Background: We present a study aimed to define the analytical goals for the determination of hemoglobin A 2 , a minor hemoglobin present in human blood normally accounting from 2.5 % to 3.3 % of total hemoglobin, and typically increased up to 6 % -7 % in subjects carriers of β -thalassemia. Methods: The analytical goals have been derived using two approaches, the first one based on biologic variation, and the second one based on the opinion of experts. Results: The data obtained by studying 17 adult non-carrier healthy subjects, from whom we took blood samples every 2 weeks for 2.0 months, indicated a small intraindividual biologic variation (CV I of 0.7 % ), with respect to a larger between-subject variation (CV G of 7.7 % ). The minimum levels for imprecision, bias and total error derived from the analysis of these data were: 0.5 % , 2.9 % and 4.5 % , respectively. The limits derived from the opinion of experts were based on a questionnaire with three clinical cases, which was circulated among two teams of international experts, and on a discussion about the clinical needs. The average total error derived from such surveys ranged between 7.0 % and 9.5 % .
Introduction
The measurement of HbA 2 is primarily used for the identification of β -thalassemia carriers with the aim to prevent the severe transfusion-dependent thalassemia disorders. Detection of carriers is easily performed in the classical phenotypes characterized by increased HbA 2 values (4.0 % -6.0 % ) together with reduced mean cell volume (MCV) and mean cell hemoglobin (MCH). However, the existence of atypical β -thalassemia carriers with near normal hematological indices and borderline HbA 2 values (3.3 % -3.8 % ) can make the diagnosis more difficult [1, 2] . Borderline HbA 2 levels are generally due to the presence of mild β + mutations or may be the consequence of a number of genetic factors, such as the interaction with other molecular defects ( α -and δ -allele), β -promoter mutations, triplication of the α -globin gene ( α α α / α α ) and KLF1 gene mutations [3, 4] . In addition, some acquired conditions (iron deficiency, megaloblastic anemia, hyperthyroidism) can affect the HbA 2 levels, contributing to the risk of misinterpretation of HbA 2 results.
Since an incorrect diagnosis may translate into major clinical implications for affected individuals, it is very important that a reliable HbA 2 measurement with a high degree of both reproducibility and accuracy is provided to clinicians [5] . To this regard, data obtained in a large external quality assessment scheme [UK NEQAS (H)] and results from a recent inter-laboratory study showed a significant bias between different routine methods for HbA 2 measurement [6, 7] . However, it is rather difficult to evaluate the actual analytical quality of HbA 2 testing since at present there is no reference measurement procedure approved for this analyte and no defined specifications for allowable analytical bias and imprecision have been defined.
With regard to the analytic performance goals, there are at least six different ways for establishing them (regulations and EQAS, biologic variation, survey of clinicians, effects on medical decisions, patterns for follow-up tests, formal decision models), as clearly reviewed [8, 9] .
The aim of this work is to define some goals for the determination of HbA 2 in human blood, and to relate them to the metrological reference system for HbA 2 under development by the IFCC Working Group on HbA 2 standardization.
Approach I: goals based on biologic variation
Experimental work has been performed on 17 apparently healthy subjects (9 men and 8 women, aged 26 -52 years) by analyzing their HbA 2 values every 2 weeks, for 2 months, as previously described [10] . The subjects were enrolled among the laboratory staff and gave their written consent to be tested. The blood samples were collected after overnight fasting and without any morning exercise. Venous blood was collected by the same experienced phlebotomist between 9:00 and 9:30 with subjects in the sitting position for 1 -5 min, with minimal stasis using a 20 G straight needle directly into 3 mL siliconized vacuum tubes containing K 2 EDTA (Terumo Europe NV, Belgium). The blood specimens were immediately aliquoted and stored at -80 ° C until analyzed all in the same run, in order to minimize the analytical variation. On each day of blood collection a whole blood cell count was performed on an aliquot of the EDTA-blood specimen by means of an automated Advia 2120 analyzer (Siemens Healthcare Diagnostics).
The determination of HbA 2 was performed by an automated HPLC system (Bio-Rad Variant II, dual kit, Bio-Rad Laboratories, Segrate, Italy) using the calibrators provided by the manufacturer. Each blood specimen was analyzed in duplicate in order to evaluate the analytical imprecision. The whole set of blood samples was analyzed over four different runs, taking care that all the specimens derived from a particular subject were analyzed within the same run. Finally, the results obtained by the HPLC analysis were adjusted in order to express each result with two decimal places in order to achieve the minimum number of significant numbers. With regard to the statistical treatment of the data, an ANOVA analysis was performed, in order to extrapolate, from the overall variance ( σ ), according to the formula:
as already described with regards to a similar study performed to obtain the analytical goals for glycated hemoglobin [11] . The analytical variance ( σ 2 anal ) was obtained, as reported above, from the analysis of the differences in the duplicates.
All the data obtained by this investigation were included in the evaluation, since no abnormalities in the other red cell parameters (total hemoglobin, MCV, MCH and hematocrit) were found. The results of such evaluations are reported in Figure 1 , where the mean HbA 2 values for each subject is reported, together with the minimum to maximum range. Just by looking at the graph, it is clearly evident how much the variability in the measured HbA 2 in each subject was smaller than that measured between subjects. More over, no statistical significant differences in the HbA 2 values were found between different genders (women, mean ± SD: 2.63 ± 0.26 % ; men: 2.74 ± 0.16 % ; t-test p = 0.265). From the data obtained so far, the analytical goals for imprecision, bias and total error were calculated ( They were asked to answer the questions related to three clinical cases, as illustrated in Table 2 .
The first case history reports on an HbA 2 test repeated over a short time (typically 1 week) from the preceding result, in order to confirm a result of difficult interpretation, such for the so-called borderline values. The second case describes a situation where another repeated test is performed, but over a longer period of time during which clinical action was undertaken (i.e., iron therapy). The third case describes a somewhat less likely situation, where the test is performed four times over 3 months without any apparent change either in the pre-analytical than in the analytical phase. None of the cases were related to any real physical patient.
Responses were collected from 10 clinicians from team A and from 83 laboratory professionals from team B. A summary of the responses is shown in Table 3 , where, together with the answers, we have tabulated the mean values and the absolute HbA 2 changes about whom we were asking opinions. The corresponding allowable total error, expressed from the hypothetical mean HbA 2 values and their absolute changes, are displayed in the fourth column of Table 3 .
As can be seen, there is a quite good agreement between the laboratory professionals and the clinicians, although a rigorous comparison cannot be done, because the number of answers collected so far was very unbalanced, with team A in a much smaller quantity in respect to team B.
Finally, another approach based on clinical needs has been already reported by our group [1] and is just briefly outlined here. Considering a subject with a true HbA 2 value of 3.6 % , the measurement error should not exceed, in relative units, of more than 7.0 % in order to exclude the possibility of misclassifying him as a β -thalassemia carrier (HbA 2 ≥ 3.8 % ) or as a non-β -thalassemia subject (HbA 2 < 3.3 % ).
Conclusions
The quantitation of HbA 2 is primarily used to diagnose, or exclude the diagnosis of β -thalassemia trait in pregnant women and other patients, or to assist with the elucidation of microcytic, hypochromic anemia [5] . Historically, when only a small number of subjects were tested there appeared to be a clear difference in HbA 2 levels between carriers and non-carriers, but recent work has shown that interpretation of results is more complicated than initially thought. The interpretation of the numerical analytical results is made more complicated for two main reasons: there are more than 200 mutations causing β -thalassemia and the HbA 2 is raised by different amounts according to the mutation [13] , and second that some medical conditions affect the percentage of HbA 2 found. An HbA 2 level of 3.5 % is often given as a cut-off point to categorize carriers from non-carriers [14] . To our knowledge, up until now only a few figures on serial measurements have been published to show how much biologic variation there is [9] , and as it happens this is very small, as would be expected for any biochemical parameter mainly regulated by genetic mechanisms. Also, given the fact that nobody would make a diagnosis only on the basis of the HbA 2 value, without knowing other important information (clinical picture, family history, whole blood cell count, iron metabolism etc.), we felt it was important to determine values considered appropriate for
Approach
Total error, % Biologic variability 4.5 Opinion of experts > 9.0 Clinical need [1] 7.0 cut-off points and variability of results which will demonstrate improvements necessary in the analytical goals for manufacturers of automated analy zers. To this regard, we have summarized our findings in Table 4 , where a minimal goal for the total error could be set at 6.9 % , a kind of a compromise between the information gained from the study on biological variation, clinical needs and opinion of experts.
Of course, the opinion of experts and clinical need may change over time, as a possible result of the improvements in the analytical aspects. Up until now, there are only few methods able to achieve an overall imprecision of < 1 % , but the scenario is continuously evolving, so it would be advisable to revise such goals in the future.
Moreover, we hope that in a couple of years the complete IFCC reference system for HbA 2 is realised, so that all manufacturers are able to calibrate by means of a common commutable certified reference material with an assigned value derived from the primary reference measurement procedure. A layout of the system this Working Group is developing is shown in Figure  2 . This is a new version of that already presented some years ago [3] , and the main new issue concerns the reference measurement procedure and the primary reference materials. Both these issues are under development, following the successful approach already developed within the sphere of glycated hemoglobin [15] . The data on the analytical goals for HbA 2 , derived by means of what presented in this document, could be regarded as an additional outcome of the aims the WG is trying to achieve.
